Sign In
Buy GSK
$50.67
-1.48 (-2.84%)
At Close: Jun 18, 2026
GSK and Amgen to add medicines to TrumpRx, Fox Business reports
08:27pm, Friday, 13'th Mar 2026
GSK and Amgen will add their medicines to TrumpRX, the prescription drug website launched by President Donald Trump's administration, Fox Business reported on �
GSK's RSV Vaccine, AREXVY, Approved in US for Expanded Age Indication in Adults Aged 18–49 Years at Increased Risk
11:44am, Friday, 13'th Mar 2026
PHILADELPHIA--(BUSINESS WIRE)--GSK's RSV vaccine, AREXVY, approved in US for expanded age indication in adults aged 18–49 years at increased risk.
GSK gets US FDA approval for expanded use of RSV vaccine
07:03am, Friday, 13'th Mar 2026
British drugmaker GSK said on Friday the U.S. Food and Drug Administration has expanded the approved age range for its respiratory syncytial virus vaccine, Arexvy, to include adults aged 18 to 4
GSK plc (GSK) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
04:22pm, Wednesday, 11'th Mar 2026
GSK plc (GSK) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
GSK Out-Licenses Rights for Rare Liver Disease Drug to Alfasigma
12:41pm, Tuesday, 10'th Mar 2026
GSK licenses linerixibat to Alfasigma for cholestatic pruritus in PBC, securing $300M upfront and potential milestone payments as the drug awaits FDA review.
FDA Approves Drug Trump Touted for Autism to Treat Other Neurological Disorder
11:16am, Tuesday, 10'th Mar 2026
The Food and Drug Administration approved leucovorin, a drug the Trump administration has touted as a potential therapy for autism, to treat cerebral folate transport deficiency, a neurological disord
GSK sells rights to rare liver disease drug for up to $690m
04:15am, Monday, 09'th Mar 2026
The British pharma giant will hand off its experimental itch treatment to Italian company Alfasigma as it focuses on broader liver disease pipeline GSK PLC (LSE:GSK, NYSE:GSK), the British pharmaceuti
GSK sells rights to rare liver disease drug for up to $690m
04:12am, Monday, 09'th Mar 2026
The British pharma giant will hand off its experimental itch treatment to Italian company Alfasigma as it focuses on broader liver disease pipeline GSK PLC...
GSK Sells Rights to Drug Candidate to Alfasigma for Up to $690 Million
03:39am, Monday, 09'th Mar 2026
Under the deal, Alfasigma will gain rights to develop, manufacture and commercialize linerixibat.
GSK licenses liver disease drug to Italy's Alfasigma
03:16am, Monday, 09'th Mar 2026
GSK has agreed to sell its worldwide rights to develop and commercialise its experimental liver disease drug linerixibat to Italian pharmaceutical company Alfasigma for �
Is It Too Late to Buy GSK After a 46% Share Price Jump?
06:58pm, Sunday, 08'th Mar 2026
GSK has handed investors a remarkable run. Over the past year, the stock climbed roughly 44% from $37.79 to $54.51.
GSK to Buy 35Pharma for $950 Million
05:05am, Wednesday, 25'th Feb 2026
GSK struck a deal to buy Canada's 35Pharma as the U.K. drugmaker seeks to bolster its exposure to diseases linked to obesity.
GSK pays $950m for a pulmonary hypertension drug designed to avoid the bleeding risk that limits rival treatments
02:47am, Wednesday, 25'th Feb 2026
GSK PLC (LSE:GSK, NYSE:GSK) has agreed to acquire Canadian biotech 35Pharma for $950 million in cash, securing a clinical-stage drug for pulmonary hypertension that its new owner believes can improve
GSK pays $950m for a pulmonary hypertension drug designed to avoid the bleeding risk that limits rival treatments
02:27am, Wednesday, 25'th Feb 2026
GSK PLC (LSE:GSK, NYSE:GSK) has agreed to acquire Canadian biotech 35Pharma for $950 million in cash, securing a clinical-stage drug for pulmonary...
GSK to buy 35Pharma for $950 million
02:18am, Wednesday, 25'th Feb 2026
GSK on Wednesday agreed to buy Canadian biopharmaceutical company 35Pharma Inc for $950 million in cash.
